View Older Stories View More Recent Stories

Oct 29, 2021 07:30AM Mydecine to Participate in Wonderland: Miami on November 8-9, 2021
Oct 27, 2021 07:30AM Mydecine Reports Successful Synthesis of Novel Tryptamine Improving the Pharmaceutical Properties of Psilocin
Oct 6, 2021 07:30AM Mydecine to Present at the KCSA Psychedelics Virtual Investor Conference on October 14th
Oct 5, 2021 07:30AM Mydecine To Supply Lead Drug Candidate, MYCO-001, for Multi-Site NIDA Grant-Funded Smoking Cessation Study Lead by Dr. Matthew Johnson
Oct 1, 2021 07:30AM Mydecine Completes Spin-Out of U.S. Cannabis Assets
Sep 24, 2021 04:40PM Mydecine Innovations Group Receives Shareholder and Court Approval for Spin-Out of Cannabis Subsidiaries
Sep 22, 2021 07:30AM Mydecine Files MYCO-003 Final Patent Application and Reports Positive Preclinical Data
Sep 2, 2021 07:30AM Mydecine to Participate in Upcoming Conferences in September 2021
Aug 24, 2021 03:30PM Mydecine Innovations Group Announces Mailing of Management Information Circular and Provides Update on Spin-Out of U.S. Cannabis Assets
Aug 18, 2021 07:30AM Mydecine Innovations Group signs five-year Master Collaboration Research Agreement with Johns Hopkins University School of Medicine
Aug 16, 2021 04:55PM Mydecine Reports Second Quarter 2021 Financial Results and Provides Business Update
Jul 28, 2021 07:30AM Mydecine to Participate in Upcoming Investor Events in August 2021
Jul 21, 2021 07:30AM Mydecine Expands Portfolio of Novel Molecules Filing New Patent for MDMA-like Compounds
Jul 13, 2021 07:30AM Mydecine Innovations Group Announces Launch of Mindleap Version 2.0
Jun 24, 2021 07:30AM Mydecine Selects Substance Use Disorder and Smoking Cessation for Novel Psychedelic Molecule MYCO-004
Jun 23, 2021 07:30AM Mydecine to Participate in the ROTH Virtual Healthcare Private Company Forum on June 28th
Jun 16, 2021 07:30AM Mydecine Unveils Artificial Intelligence Drug Discovery Program
Jun 8, 2021 07:30AM Mydecine Discovers Over 40 Groundbreaking Potential Pharmacologically Active Novel Compounds in Mushrooms
Jun 3, 2021 07:30AM Mydecine to Participate in the H.C. Wainwright Psychedelics in Psychiatry and Beyond Conference on June 17th
May 25, 2021 07:30AM Health Canada Approves Expansion of Mydecine’s Cultivation Capabilities for Psilocybin Producing Mushrooms
May 19, 2021 07:30AM Mydecine Provides Update on Spin-Out of U.S. Cannabis Assets
May 18, 2021 07:30AM Mydecine Reports First Quarter 2021 Financial Results and Provides Business Update
May 10, 2021 07:30AM Mydecine to Participate in the Benzinga Global Small Cap Conference on May 13th
May 5, 2021 07:30AM Mydecine Announces Partnership with LeadGen Labs
May 3, 2021 07:30AM Mydecine Reports Full Year 2020 Financial Results and Provides Business Update
Apr 26, 2021 07:30AM Mydecine to Report Full Year 2020 Financial Results on May 3, 2021
Apr 13, 2021 07:30AM Mydecine Announces Launch of Cutting-Edge Therapeutic Compound Screening
Apr 7, 2021 07:30AM Mydecine Announces API-naming structure of Four Lead Candidates and Prepares for Pre-IND
Apr 7, 2021 07:30AM Mydecine Announces Four Lead Novel Drug Candidates and Prepares for Pre-IND Meetings with the FDA and Health Canada To Prepare For Human Clinical
Mar 23, 2021 09:30AM Mydecine Innovations Group Graduates Listing To NEO Exchange
Mar 23, 2021 07:30AM Mydecine Innovations Group Announces Migration to NEO Exchange
Mar 16, 2021 07:30AM Mydecine Innovations Group Provides Update on European Operations
Mar 1, 2021 07:30AM Mydecine Fully Completes the First-Ever International Export of Psilocybin Mushrooms and Solidifies its Clinical and Commercial Supply Chain
Feb 12, 2021 09:08AM Mydecine Innovations Group Announces Closing of $17,250,000 Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option
Feb 9, 2021 02:29PM Mydecine Innovations Group Files Final Prospectus in Connection with Bought Deal Offering of Units
Feb 5, 2021 08:06AM Mydecine Innovations Group Files Amended and Restated Financial Statements
Feb 3, 2021 07:30AM Mydecine Innovations Group Appoints Josephine Wu to Board of Directors
Feb 1, 2021 07:30AM Mydecine Innovations Group Receives Conditional Approval to List on NEO Exchange
Jan 28, 2021 07:30AM Mydecine Innovations Group Sponsors Study on Neuron Level Response to Psilocybin at University of Maryland
Jan 27, 2021 07:30AM Mydecine Innovations Group Files Application to list to the NASDAQ
Jan 22, 2021 07:30AM Mydecine Innovations Group Included in First-Ever Psychedelics ETF
Jan 21, 2021 04:20PM Mydecine Innovations Group Files Preliminary Prospectus in Connection with Bought Deal Offering of Units
Jan 20, 2021 11:00AM Mydecine Innovations Group Upsizes Previously Announced Bought Deal
Jan 20, 2021 10:58AM Mydecine Innovations Group Announces C$10 Million Bought Deal Offering of Units
Jan 11, 2021 07:30AM Mydecine Innovations Group Appoints Gordon Neal to Board of Directors and Dean Ditto as Chief Financial Officer
Jan 7, 2021 07:30AM Mydecine Innovations Group Shares Intellectual Property Update
Jan 5, 2021 07:30AM Mydecine Innovations Group Sponsors First Lab-Based Study of Established Microdosers at Macquarie University in Australia
Dec 21, 2020 07:30AM Mydecine Innovations Group Engages ethica CRO as Contract Research Organization Partner for Phase 2A PTSD Clinical Trials
Dec 15, 2020 07:30AM Mydecine Innovations Group Engages the ProPharma Group to Proceed with FDA Filings and Approval for Novel Research and Multiple Phase Clinical Trials
Dec 10, 2020 07:30AM Mydecine Innovations Group Partners with Microdose Psychedelic Insights to Present a Free, Live Webinar Series on The Renaissance of Psychedelics
View More Recent Stories View Older Stories